Halper Sadeh LLC is investigating whether shareholders of Forte Biosciences (FBRX) and Safety Insurance Group (SAFT) received fair treatment in their recent sales to argenx and Mapfre affiliates, respectively. The firm suspects insiders may have gained financial benefits not available to ordinary shareholders and that deal terms might restrict better competing offers. Shareholders are encouraged to contact Halper Sadeh LLC to explore their rights and potential claims for increased compensation or disclosures. This investigation highlights concerns about fairness and transparency in these corporate transactions.
AGC Biologics has signed a multi-year commercial manufacturing agreement with a major pharmaceutical company for its new Yokohama facility, locking in half of the mammalian cell production capacity. The deal, worth hundreds of millions of dollars, co...
AGC Biologics has signed a multi-year commercial manufacturing contract valued at hundreds of millions of dollars with a major biopharma company for its new Yokohama facility. The contract covers production of five biopharmaceutical programs, securin...
AGC Biologics has secured a long-term commercial manufacturing contract with a global biopharma company for its new Yokohama facility, expected to generate hundreds of millions of dollars. The contract covers production of five biopharmaceutical prod...
Seagate Technology reported strong Q4 2026 results, beating earnings per share estimates with $5.71 and revenue of $3.63 billion, driven by high demand for data storage from the AI sector. The company showed solid financial health with a low debt-to-...
Audiera (BEAT) fell sharply by 24.29%, breaking below the $3 support level to a low of $2.4 before slightly recovering to around $2.76. The drop followed increased selling pressure with significant outflows in both futures and spot markets, indicatin...
